0 296

Cited 0 times in

Cited 11 times in

Defining Minimum Treatment Parameters of Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma: An Expert Consensus

Authors
 Yanagihara, Ted K.  ;  Tepper, Joel E.  ;  Moon, Andrew M.  ;  Barry, Aisling  ;  Molla, Meritxell  ;  Seong, Jinsil  ;  Torres, Ferran  ;  Apisarnthanarax, Smith  ;  Buckstein, Michael  ;  Cardenes, Higinia  ;  Chang, Daniel T.  ;  Feng, Mary  ;  Guha, Chandan  ;  Hallemeier, Christopher L.  ;  Hawkins, Maria A.  ;  Hoyer, Morten  ;  Iwata, Hiromitsu  ;  Jabbour, Salma K.  ;  Kachnic, Lisa  ;  Kharofa, Jordan  ;  Kim, Tae Hyun  ;  Kirichenko, Alexander  ;  Koay, Eugene J.  ;  Makishima, Hirokazu  ;  Mases, Joel  ;  Meyer, Jeffrey J.  ;  Munoz-Schuffenegger, Pablo  ;  Owen, Dawn  ;  Park, Hee Chul  ;  Saez, Jordi  ;  Sanford, Nina N.  ;  Scorsetti, Marta  ;  Smith, Grace L.  ;  Wo, Jennifer Y.  ;  Yoon, Sang Min  ;  Lawrence, Theodore S.  ;  Reig, Maria  ;  Dawson, Laura A. 
Citation
 PRACTICAL RADIATION ONCOLOGY, Vol.14(2) : 134-145, 2024-03 
Journal Title
PRACTICAL RADIATION ONCOLOGY
ISSN
 1879-8500 
Issue Date
2024-03
Abstract
Purpose: External beam radiation therapy (EBRT) is a highly effective treatment in select patients with hepatocellular carcinoma (HCC). However, the Barcelona Clinic Liver Cancer system does not recommend the use of EBRT in HCC due to a lack of sufficient evidence and intends to perform an individual patient level meta -analysis of ablative EBRT in this population. However, there are many types of EBRT described in the literature with no formal definition of what constitutes "ablative." Thus, we convened a group of international experts to provide consensus on the parameters that define ablative EBRT in HCC. Methods and Materials: Fundamental parameters related to dose, fractionation, radiobiology, target identification, and delivery technique were identified by a steering committee to generate 7 Key Criteria (KC) that would define ablative EBRT for HCC. Using a modified Delphi (mDelphi) method, experts in the use of EBRT in the treatment of HCC were surveyed. Respondents were given 30 days to respond in round 1 of the mDelphi and 14 days to respond in round 2. A threshold of >= 70% was used to define consensus for answers to each KC. Results: Of 40 invitations extended, 35 (88%) returned responses. In the first round, 3 of 7 KC reached consensus. In the second round, 100% returned responses and consensus was reached in 3 of the remaining 4 KC. The distribution of answers for one KC, which queried the a/b ratio of HCC, was such that consensus was not achieved. Based on this analysis, ablative EBRT for HCC was defined as a BED10 >= 80 Gy with daily imaging and multiphasic contrast used for target delineation. Treatment breaks (eg, for adaptive EBRT) are allowed, but the total treatment time should be <= 6 weeks. Equivalent dose when treating with protons should use a conversion factor of 1.1, but there is no single conversion factor for carbon ions. Conclusions: Using a mDelphi method assessing expert opinion, we provide the first consensus definition of ablative EBRT for HCC. Empirical data are required to define the a/b of HCC. (c) 2023 Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.
DOI
10.1016/j.prro.2023.08.016
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Seong, Jin Sil(성진실) ORCID logo https://orcid.org/0000-0003-1794-5951
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/199227
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links